Navigation Links
DOR BioPharma Announces Potential $30 Million North American Partnership Agreement with Sigma-Tau Pharmaceuticals for orBec(R) in the Treatment of Graft-versus-Host Disease
Date:2/12/2009

Phase 3 trial costs] that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the US Government or other countries, that the US Congress may not pass any legislation that would provide additional funding for the Project BioShield program, that it will be able to patent, register or protect its technology from challenge and products from competition or maintain or expand its license agreements with its current licensors, or that its business strategy will be successful. Important factors which may affect the future use of orBec(R) for gastrointestinal GVHD include the risks that: the FDA's requirement that DOR conduct additional clinical trials to demonstrate the safety and efficacy of orBec(R) will take a significant amount of time and money to complete and positive results leading to regulatory approval cannot be assumed; DOR is dependent on the expertise, effort, priorities and contractual obligations of third parties in the clinical trials, manufacturing, marketing, sales and distribution of its products; orBec(R) may not gain market acceptance if it is eventually approved by the FDA; and others may develop technologies or products superior to orBec(R). These and other factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, DOR's most recent reports on Forms 10-Q and 10-KSB. Unless required by law, DOR assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.


'/>"/>
SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. PDL BioPharma to Actively Seek Sale of Entire Company or Its Key Assets
2. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
3. Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting
4. Nabi Biopharmaceuticals Completes Sale of Nabi Biologics to Biotest AG
5. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
6. Aladdin eToken First Strong Authentication Device to Achieve Certification from the SAFE-BioPharma Association
7. XTL Biopharmaceuticals Announces Financial Results for the Year Ended December 31, 2007
8. ARCA Discovery Changes Name to ARCA biopharma to Reflect Focus on Drug Commercialization
9. CeNeRx BioPharma Appoints Mahnaz Asgharnejad as Vice President of Clinical Development
10. Immunosyn Announces Proposed Agreements for Distribution of the Biopharmaceutical SF-1019 in Utah
11. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... Mauritius is a seemingly idyllic and tranquil ... km (1,243 miles) off the southeastern coast of Africa, ... melting pot where everyone lives together in harmony. , ... is riddled with drug abuse. In fact, it carries ... of any nation in eastern Africa. , “Many youngsters, ...
(Date:4/20/2015)... April 20, 2015 “Consumers deserve to know ... washing their children’s hair will not put their health at ... of the National Alliance for Hispanic Health, the nation’s leading ... FDA has not had authority to ensure cosmetic and personal ... has FDA had authority to get products off the shelves ...
(Date:4/20/2015)... Advance Home Care Supply understands that ordering adult ... prefer not to share with others. As such, the company ... allowing customers to order the products and supplies they need ... a neighbor or passerby knowing what the customer has purchased. ... orders and no minimum order limit is required. Also, there ...
(Date:4/20/2015)... TROY Healthcare Solutions will be hosting ... software, which provides the ultimate level of security for ... the Anthem Suite Hotel in the Socrates Room, located ... , Beginning at 7 AM, TROY Healthcare Solutions will ... Healthcare Solutions will offer brief 15-20 minute presentations each ...
(Date:4/20/2015)... (PRWEB) April 20, 2015 Grateful Dead ... were united as one until 1995. The group was more ... blues, reggae, rock, bluegrass, folk, space rock, country, and other ... as the ultimate jam band. The group was inducted into ... in total has sold more than 35 million records worldwide. ...
Breaking Medicine News(10 mins):Health News:Voice For Humanity: Choolun Bhojoo leads the fight to rid Mauritius of a drug plague 2Health News:Statement of National Alliance for Hispanic Health on Senate Introduction of Personal Care Products Safety Act 2Health News:Advance Home Care Supply Proud to Offer Discreet Delivery For All Orders 2Health News:Advance Home Care Supply Proud to Offer Discreet Delivery For All Orders 3Health News:TROY Healthcare to Offer Prescription Solutions that Could Save a Health System $100,000 2Health News:TROY Healthcare to Offer Prescription Solutions that Could Save a Health System $100,000 3Health News:Grateful Dead Tickets at Levi’s Stadium in Santa Clara: Ticket Down Slashes Grateful Dead Tickets in Santa Clara @ Levi’s Stadium for "Fare Thee Well" 50th Anniversary 2
... , OAKLAND, Calif., Aug. 5 Anyone ... record in a standardized format understood at hospitals, clinics and ... specializing in chronic illness support, geriatric care management and private ... Your Own Health to re-brand and sell the popular ...
... , , PHOENIX, Aug. 5 ... hand must not become a vehicle for taking lives through abortion ... report at the organization,s 127th annual convention here today. Referring to ... declared that "Health care reform must be abortion-free." , , ...
... direction for diabetes treatment , WEDNESDAY, Aug. 5 (HealthDay News) ... role in the control of blood sugar production in the ... first time that CCK from the gut activates receptors to ... axis," Tony Lam of the University of Toronto said in ...
... , , , ... a privately-held specialty pharmaceutical company, today announced that it has ... IMS data indicates the combined U.S. market for these two ... and shipping both products immediately. , , ...
... an animal model that provides strong evidence why imatinib, marketed ... but does not keep the disease from returning if treatment ... drug,s radar and enable the disease to recur in most ... issue of Cancer Cell . The researchers ...
... An internationally recognized Virginia Commonwealth University physician has ... Award for his pioneering contributions that have advanced the ... past recipients who have made a remarkable impact on ... Foundation for Infectious Diseases awarded the honor to Richard ...
Cached Medicine News:Health News:Portable Health Care Records Now Available for Consumers 2Health News:'Health Care Reform Must be Abortion-Free,' says Supreme Knight 2Health News:Sagent Pharmaceuticals Announces Launch of First Two Oncolytic Products: Fludarabine Phosphate for Injection, USP and Epirubicin Hydrochloride Injection 2Health News:Finding key to cancer drug Gleevec's limitations 2Health News:National Foundation for Infectious Diseases honors VCU physician with Maxwell Finland Award for 2010 2Health News:National Foundation for Infectious Diseases honors VCU physician with Maxwell Finland Award for 2010 3
(Date:4/20/2015)... DIEGO , April 20, 2015  Halozyme ... company developing novel oncology and drug-delivery therapies, today ... the American Association for Cancer Research (AACR) annual ... results of its randomized Phase 2 study in ... annual meeting of the American Society of Clinical ...
(Date:4/20/2015)... PALO ALTO, Calif. , April 20, 2015 ... study demonstrate positive trends in the ability of ... slow the progression of amyotrophic lateral sclerosis (ALS, ... over a 6-month treatment period. While NP001,s slowing ... of the study was not statistically significant, clinically ...
(Date:4/20/2015)...  OpGen, Inc., a molecular testing and bioinformatics ... management team with the appointments of former Foundation ... Krenitsky , M.D. as president, and Timothy ... With more than 15 years ... biotechnology operations, including senior commercial and operational responsibilities ...
Breaking Medicine Technology:Halozyme Presents New Preclinical Data At The American Association for Cancer Research Annual Meeting, Announces Clinical Data Presentation At ASCO 2Halozyme Presents New Preclinical Data At The American Association for Cancer Research Annual Meeting, Announces Clinical Data Presentation At ASCO 3Halozyme Presents New Preclinical Data At The American Association for Cancer Research Annual Meeting, Announces Clinical Data Presentation At ASCO 4Halozyme Presents New Preclinical Data At The American Association for Cancer Research Annual Meeting, Announces Clinical Data Presentation At ASCO 5Published Phase 2 Results Demonstrate Neuraltus Pharmaceuticals' NP001 Potential Efficacy and Safety in ALS 2Published Phase 2 Results Demonstrate Neuraltus Pharmaceuticals' NP001 Potential Efficacy and Safety in ALS 3Published Phase 2 Results Demonstrate Neuraltus Pharmaceuticals' NP001 Potential Efficacy and Safety in ALS 4Published Phase 2 Results Demonstrate Neuraltus Pharmaceuticals' NP001 Potential Efficacy and Safety in ALS 5OpGen Appoints Industry Veterans Dr. Kevin Krenitsky as President and Timothy Dec as Interim Chief Financial Officer 2OpGen Appoints Industry Veterans Dr. Kevin Krenitsky as President and Timothy Dec as Interim Chief Financial Officer 3OpGen Appoints Industry Veterans Dr. Kevin Krenitsky as President and Timothy Dec as Interim Chief Financial Officer 4
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: